These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 39044306)

  • 1. Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.
    Shamim MA; Patil AN; Amin U; Roy T; Tiwari K; Husain N; Kumar J; Chenchula S; Rao P; Ganesh V; Varthya SB; Singh S; Shukla R; Rastogi A; Gandhi AP; Satapathy P; Sah R; Padhi BK; Dwivedi P; Khunti K
    Diabetes Obes Metab; 2024 Oct; 26(10):4302-4317. PubMed ID: 39044306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.
    Dai M; Dai S; Gu L; Xiang Z; Xu A; Lu S; Yang Y; Zhou C
    J Clin Res Pediatr Endocrinol; 2024 Sep; 16(3):323-333. PubMed ID: 38828884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
    Liu Y; Ruan B; Jiang H; Le S; Liu Y; Ao X; Huang Y; Shi X; Xue R; Fu X; Wang S
    Am J Clin Nutr; 2023 Sep; 118(3):614-626. PubMed ID: 37661106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
    Xie Z; Hu J; Gu H; Li M; Chen J
    Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
    Guo X; Zhou Z; Lyu X; Xu H; Zhu H; Pan H; Wang L; Yang H; Gong F
    Horm Metab Res; 2022 Jul; 54(7):458-471. PubMed ID: 35512849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
    Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
    BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.
    Yuan X; Gao Z; Yang C; Duan K; Ren L; Song G
    Front Endocrinol (Lausanne); 2023; 14():1170881. PubMed ID: 37342259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
    Rivera FB; Lumbang GNO; Gaid DRM; Cruz LLA; Magalong JV; Bantayan NRB; Lara-Breitinger KM; Gulati M; Bakris G
    Diabetes Obes Metab; 2024 Jun; 26(6):2209-2228. PubMed ID: 38505997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
    Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
    Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
    Xie Z; Zheng G; Liang Z; Li M; Deng W; Cao W
    Metabolism; 2024 Dec; 161():156038. PubMed ID: 39305981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Ji L; Zhan S
    Endocrine; 2015 Apr; 48(3):794-803. PubMed ID: 25115635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
    Madsbad S
    Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.